Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer

Affiliations

¹ Academic Urology Unit, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. Electronic address: s.conroy@sheffield.ac.uk.
² Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.

Editorial

Samantha Conroy et al. Eur Urol. 2022 Sep.

. 2022 Sep;82(3):271-272.

doi: 10.1016/j.eururo.2022.04.006. Epub 2022 May 5.

¹ Academic Urology Unit, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. Electronic address: s.conroy@sheffield.ac.uk.
² Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.

No abstract available

Comment on

Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G, Koren A, Lardeau CH, Mohr T, Haitel A, Compérat E, Oszwald A, Wasinger G, Clozel T, Elemento O, Kubicek S, Berger W, Shariat SF. Ertl IE, et al. Eur Urol. 2022 Sep;82(3):261-270. doi: 10.1016/j.eururo.2022.03.009. Epub 2022 Apr 4. Eur Urol. 2022. PMID: 35393162